Bayer and Curadev Pte Ltd. announced in late March 2020 the signing of a research collaboration and license agreement for Curadev’s Stimulator of Interferon Genes (STING) antagonist program.
Collaboration between Bayer and Curadev aims to discover new drug candidates for the treatment of lung disease, cardiovascular disease, and other inflammatory diseases. STING antagonists has shown to offer tremendous potential for new treatments as STING is known to play a role in activating the innate immune system in auto-inflammatory disease.
“In line with our strategy, we continue to deepen our understanding of pathology in disease areas with high unmet medical need and further strengthen our research activities on mechanisms with broader potential, rather than individual indications,” said Dr. Joerg Moeller, Member of the Executive Committee of Bayer AG’s Pharmaceuticals Division and Head of Research and Development. “We are continuously looking for new breakthroughs to improve patients’ lives and Curadev’s deep experience working on the STING pathway makes them an ideal partner.”
Curadev’s small molecule STING antagonist program aims to discover and develop inhibitors of the intracellular stimulator of interferon genes (STING) pathway. Within the agreement, Bayer will be allowed exclusive access to novel molecules from Curadev that are designed to inhibit the STING pathway. Both companies will collaborate to optimize and advance these molecules, as well as other generated during the collaboration, into clinical development.
“Curadev identified STING as a versatile target where both agonists and antagonists can play an important role in diverse disease conditions,” said Dr. Arjun Surya, Co-Founder & Chief Scientific Officer of Curadev. “The agile and collaborative approach of Bayer in Bayer and Curadev sign research collaboration and license agreement to develop novel STING antagonists across indications building this partnership convinces us that we have found the ideal partner to develop our portfolio of STING antagonists for various disease indications.”
Additionally, in the terms of the agreement, Curadev will receive an upfront payment and research funding during the research term. It may also be eligible for pre-clinical, clinical and sales milestones of potentially over EUR 250 million as well as royalties of single digit percentages net sales.
The collaboration was facilitated by the Pharmaceuticals Business Development and Licensing team from Bayer. [APBN]